StudyFinder

MT2016-11 :Autologous Stem Cell Transplant In Patients with Hodgkin Lymphoma (HL) and Non-Hodgkin Lymphomas (NHL)

Status: Recruiting

The primary objective is to estimate overall survival (OS) at 3 years post-transplant for patients who received the radiation free preparative regimen BEAM.

I'm interested

Age: Not specified
Healthy Volunteers:
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• up to 75 years of age
• diagnosis of Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Mature B cell Lymphoma, or Mature T cell Lymphoma
• at least 4 weeks from previous chemotherapy; 6 weeks from nitrosoureas
• women of child bearing potential and sexually active males with partners of child bearing potential must agree to use adequate birth control for the duration of treatment
• see link to clinicaltrials.gov for complete criteria
Exclusion Criteria:

• women who are pregnant or breastfeeding
• chemotherapy resistant disease
• unrelated active infection
Interventions:

Drug: AraC, Drug: BCNU, Drug: Cyclophosphamide, Drug: Etoposide, Biological: G-CSF, Drug: Melphalan, Procedure: Peripheral blood stem cell transplantation, Radiation: Total Body Irradiation

Conditions:

Cancer

Keywords:

Clinics and Surgery Center (CSC), Hodgkin Lymphoma, Non-Hodgkin Lymphoma

Contact(s): Veronika Bachanova - bach0173@umn.edu
Principal Investigator: Veronika Bachanova, MD
Phase: PHASE2
IRB Number: 1611M99805
System ID: 19183
See this study on ClinicalTrials.gov

Back